Accessibility Menu
Pacific Edge logo

Pacific Edge(ASX) PEB

Market CapA$267.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-86%
5 YearN/A
1 Year+126%
1 Month-10%
A$0.22
+0.00%
+0.00Today
Pacific Edge last closing stock price
MetricPriceDate
Last closeAUD 0.222026-08-12
Pacific Edge stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.42%AUD 0.242026-08-05
1 month-10.42%AUD 0.242026-07-13
3 month+48.28%AUD 0.152026-05-14
Year to date+34.37%AUD 0.162025-12-31
1 year+126.32%AUD 0.102025-08-12
3 year+79.17%AUD 0.122023-08-09
Since inception-86.04%AUD 1.542021-09-27

Pacific Edge Financials at a Glance

Market Cap

A$267.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

NZ$34.24M

Net Income (TTM)

-NZ$65.72M

EPS (TTM)

-A$0.03

P/E Ratio

-6.29

Dividend

A$0.00

Beta (Volatility)

-0.23 (Low)

Price

A$0.22

Volume

0

Open

A$0.22

Previous Close

A$0.22

Daily Range

A$0.22 - A$0.22

52-Week Range

A$0.09 - A$0.27

Estimated Earnings Date

Nov 19, 2026

PEB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pacific Edge

Pacific Edge Limited is a cancer diagnostics firm based in Dunedin, New Zealand, focused on developing advanced diagnostic tools for cancer management. Established in 2001, the company operates in New Zealand, the United States, Australia, and Singapore, with a strong emphasis on bladder cancer diagnostics.

Products and Services
  • Cxbladder suite of genomic urine tests for bladder cancer
  • Cxcolorectal, a prognostic gene signature for colorectal cancer
  • Pipeline includes diagnostics for gastric, colorectal, and endometrial cancers
Growth Outlook
  • Expansion of Cxbladder product line enhances market presence
  • Increased focus on research and development to drive innovation
  • Strategic partnerships may boost distribution and sales channels
Financial Highlights
  • Recent quarterly revenue of NZD 5.6 million, showing potential growth
  • Cash and short-term investments totaled NZD 7.8 million as of March 2026
  • Operating expenses reached NZD 17.6 million, indicating investment in growth
Pacific Edge Limited is dedicated to improving cancer diagnostics through innovative products. The company's flagship offering, Cxbladder, is designed to assist in the detection and management of bladder cancer, a significant health concern globally. With a robust pipeline that includes additional cancer diagnostics, Pacific Edge is positioned to capitalize on the growing demand for early detection and personalized treatment options in oncology. The growth outlook for Pacific Edge is promising, driven by the expansion of its product offerings and a commitment to research and development. The company is actively pursuing strategic partnerships to enhance its market reach and distribution capabilities, which could lead to increased sales and revenue growth. Financially, Pacific Edge has shown resilience, with a recent quarterly revenue of NZD 5.6 million. The company maintains a solid cash position, with NZD 7.8 million in cash and short-term investments, providing a buffer for ongoing operations and development initiatives. While operating expenses are significant, they reflect the company's commitment to investing in future growth and innovation in the cancer diagnostics sector.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Peter Meintjes, PhD

Website

www.pacificedgedx.com

Headquarters

Dunedin, OTA 9016, NZ

PEB Financials

Key Financial Metrics (TTM)

Gross Margin

-0.93%

Operating Margin

-329.05%

Net Income Margin

-311.14%

Return on Equity

-190.54%

Return on Capital

-316.80%

Return on Assets

-203.26%

Earnings Yield

-15.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$267.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.24B

Volume

0

Avg. Volume

59.03K

Financials (TTM)

Gross Profit

NZ$10.15M

Operating Income

-NZ$82.58M

EBITDA

-NZ$66.06M

Operating Cash Flow

-NZ$56.62M

Capital Expenditure

-NZ$984.07K

Free Cash Flow

-NZ$57.68M

Cash & ST Invst.

NZ$7.83M

Total Debt

NZ$1.29M

Pacific Edge Performance Analysis

Pacific Edge annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31NZD 17,873,99765.7%
20242024-03-31NZD 22,162,89724.0%
20252025-03-31NZD 19,886,249-10.3%
20262026-03-31NZD 10,217,969-48.6%
Pacific Edge sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-300.6%
Q42025-03-310.5%
Q22025-09-30-48.3%
Q42026-03-31-4.9%
Pacific Edge annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31NZD -0.0324.7%
20242024-03-31NZD -0.0311.6%
20252025-03-31NZD -0.03-0.6%
20262026-03-31NZD -0.030.3%
Pacific Edge sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-3.4%
Q42025-03-31-5.0%
Q22025-09-30-15.3%
Q42026-03-3124.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

NZ$5.60M

-50.3%

Gross Profit

-NZ$163.18K

-102.9%

Gross Margin

-2.91%

N/A

Market Cap

A$267.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.34M

N/A

Employees

114

N/A

Net Income

-NZ$16.78M

-17.5%

EBITDA

-NZ$16.41M

-5.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

NZ$7.83M

-84.4%

Total Debt

NZ$1.29M

-68.2%

Accounts Receivable

NZ$2.48M

-51.6%

Inventory

NZ$2.05M

+21.7%

Long Term Debt

NZ$126.92K

-94.9%

Short Term Debt

NZ$1.17M

-25.4%

Return on Assets

-2.03%

N/A

Return on Invested Capital

-3.51%

N/A

Free Cash Flow

-NZ$13.07M

-17.7%

Operating Cash Flow

-NZ$13.01M

-20.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVH.AXAVITA Medical, Inc.
A$2.28+0.00%
SPL.AXStarpharma Holdings Limited
A$0.73+4.32%
NYR.AXNyrada Inc.
A$0.71-8.39%
EMV.AXEMVision Medical Devices Ltd
A$1.73-1.98%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.56+0.02%
CDECoeur Mining
$18.45-0.02%
TAT&T
$24.58+0.01%
SMRNuScale Power
$9.85+0.03%

Questions About PEB

What is the current price of Pacific Edge?

Pacific Edge is trading at A$0.22 per share.

What is the 52-week range for Pacific Edge?

Over the past 52 weeks, Pacific Edge has traded between A$0.09 and A$0.27.

How much debt does Pacific Edge have?

As of the most recent reporting period, Pacific Edge reported total debt of NZ$1.07M.

How much cash does Pacific Edge have on hand?

Pacific Edge reported NZ$6.48M in cash and cash equivalents in its most recent financial results.

What is Pacific Edge’s dividend yield?

Pacific Edge does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services